Effects of psilocybin on cognition and emotional processing in treatment resistant depression
Abstract
Major depressive disorder (MDD) is associated with significant cognitive and emotional processing differences relative to the general population. For example, those with MDD show slower processing speed, memory difficulties, and impairments in attention. These differences can significantly impact daily functioning and quality of life. In the emotional domain, those with MDD show a bias towards negative emotional stimuli and emotion regulation impairments, which are suggested to underlie many core depressive symptoms, and may be a target for treatment. Around 30-50% of those with MDD do not respond to first-line treatment options (including antidepressant medications and psychological therapies), termed treatment resistant depression (TRD). Psilocybin (4-phosphoryloxyl-N,N-dimethyltryptamine), a natural tryptamine occurring in psilocybe mushrooms, has shown promise in the treatment of TRD. The Psilocybin in Depression Resistant to standard treatments (PsiDeR) trial was a two arm, double-blind, randomised, placebo-controlled phase 2 trial evaluating feasibility and safety of psilocybin versus placebo in adults with TRD. This analysis will examine effects of psilocybin versus placebo on both objective and perceived cognitive functioning and emotional processing at 1 week and 6 week follow-up. An exploratory analysis will investigate whether changes in cognitive and emotional processing are related to changes in depression (Montgomery Asberg Depression Rating Scale (MADRS) scores).
Topics & conditions
Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.
Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.